Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil

Rosângela Maria Gomes*, Augusto Afonso Guerra Júnior, Lívia Lovato Pires de Lemos, Juliana de Oliveira Costa, Alessandra Maciel Almeida, Juliana Alvares, Charles Simão Filho, Mariângela Leal Cherchiglia, Eli Iola Gurgel Andrade, Brian Godman, Francisco Assis Acurcio

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Background: Cyclosporine and tacrolimus are well established immunosuppressants; however little is known about long term survival rates. The project aim was to compare 10-year graft survival and associated factors among kidney transplant patients within the Brazilian Public Health System (SUS) prescribed either immunosuppressant. Methods: Analyze a national cohort of kidney transplant recipients within SUS. Graft loss defined by death or dialysis for more than three months. Kaplan-Meier method used to estimate cumulative probabilities of survival. Cox proportional hazards model used to evaluate factors associated with progression to graft loss. Results: 13,811 patients were included, 5,887 used cyclosporine and 7,924 tacrolimus. A higher risk of graft loss was associated with tacrolimus, a deceased donor, additional years of age, median period of dialysis greater than 47 months, diagnosis of diabetes as the primary cause of chronic kidney disease and transplantation between 2005 and 2009. Conclusions: Among other factors, tacrolimus-based regimens were associated with worse graft survival.

Original languageEnglish
Pages (from-to)991-999
Number of pages9
JournalExpert Review of Clinical Pharmacology
Volume9
Issue number7
DOIs
Publication statusPublished - 2 Jul 2016
Externally publishedYes

Keywords

  • Brazil
  • Cyclosporine
  • Graft survival
  • Immunosuppressants
  • Kidney transplantation
  • Survival rates
  • Tacrolimus

Fingerprint

Dive into the research topics of 'Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil'. Together they form a unique fingerprint.

Cite this